Daclatasvir Dihydrochloride Patent Expiration
Daclatasvir Dihydrochloride is used for treating hepatitis C virus infections. It was first introduced by Bristol-Myers Squibb Co
Daclatasvir Dihydrochloride Patents
Given below is the list of patents protecting Daclatasvir Dihydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Daklinza | US8329159 | Hepatitis C virus inhibitors | Jul 24, 2029 | Bristol-myers Squibb |
| Daklinza | US8629171 | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt | Jun 13, 2031 | Bristol-myers Squibb |
| Daklinza | US8642025 | Hepatitis C virus inhibitors | Aug 11, 2027 | Bristol-myers Squibb |
| Daklinza | US8900566 | Hepatitis C virus inhibitors | Aug 08, 2027 | Bristol-myers Squibb |
| Daklinza | US9421192 | Hepatitis C virus inhibitors | Aug 08, 2027 | Bristol-myers Squibb |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳